India's largest software exporter Tata Consultancy Services announced a $2.18 billion share buyback plan on Wednesday, even as its profits fell amid the financial fallout from the coronavirus pandemic and an American legal case.
The country's second-most valuable firm by market size said net profit slumped by 7.1 percent to 74.75 billion rupees ($1.02 billion) for the July-September quarter compared to the previous corresponding period.
The company said it had also set aside 12.18 billion rupees under exceptional items for damages for a US litigation.
"The strong order book, a very robust deal pipeline, and continued market share gains give us confidence for the future," TCS chief executive Rajesh Gopinathan said in a statement.
Analysts said the share buyback was due to the ongoing legal tussle between its parent company Tata Sons and one of their oldest shareholders, The Shapoorji Pallonji Group.
The group has a 18.4 percent stake in Tata Sons but has indicated it wants to pull out of the salt-to-steel behemoth.
TCS was at the forefront of an IT boom that saw the country become a back office to the world as firms in developed nations subcontracted work, taking advantage of a skilled English-speaking workforce.
TCS earns more than 80 percent of its revenues from Western markets including Britain, the United States and Europe.
But the Covid-19 pandemic has battered demand for the firm's services in the financial and banking sectors.
Shares of TCS closed almost one percent higher on the Bombay Stock Exchange Sensex Index in Mumbai ahead of the results being released.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.